The ASTCT Pharmacy SIG Steering Committee created an FAQ document to answer questions regarding the Fludarabine Shortage for HCT and CAR T Cell Recipients. ASTCT 2022 National Fludarabine Shortage for HCT and CAR-T Cell Recipients: Frequently Asked Questions.

The FAQ has guidance on:

• Conservation efforts of Fludarabine supply
• Conditioning regimens for HCT recipients
• Pharmacologic considerations of alternate purine nucleoside analogues
• Lymphodepletion for CAR T-cell recipients
• Pediatric considerations
• PO Fludarabine

DOWNLOAD FAQs
 

Contributors to the FAQs document include: Terri Lynn Shigle, PharmD; Ben Andrick, PharmD; Katie Gatwood, PharmD; Alison Gulbis, PharmD; Amanda Seddon, PharmD; Ashley Teusink-Cross, PharmD; Colleen Timlin, PharmD; Jamie Ziggas, PharmD; Mehdi Hamadani, MD; Paul Carpenter, MD; Miguel-Angel Perales, MD; Brenda Sandmaier, MD; Ryan Shaw, PharmD